Fifth Third Bancorp
NAVB

Fifth Third Bancorp’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Fifth Third Bancorp’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50
Closed – – 2419
2018
Q1 		$0 Buy
+50
New +$374 ﹤0.01% 2462

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fifth Third Bancorp's NAVB Position: Q2 2018 in Review

Fifth Third Bancorp sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2018, closing a stake of 50 shares.

Fifth Third Bancorp first reported a position in NAVB in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 54 funds tracked by Wall St. Rank hold NAVB as of Q2 2018.

  • Fifth Third Bancorp reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Fifth Third Bancorp sold 50 Navidea Biopharmaceuticals Inc. shares in Q2 2018.
  • Fifth Third Bancorp first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2018 and held it in 1 quarter.
  • Fifth Third Bancorp's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q1 2018.
  • 54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2018.

Based on Fifth Third Bancorp's 13F filing for Q2 2018, filed 14 Aug 2018.